Article
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
The International journal of biological markers - 9 Dec 2014
Cecchin Erika, De Mattia Elena, Mazzon Giorgio, Cauci Sabina, Trombetta Carlo, Toffoli Giuseppe
Abstract excerpt
Finasteride is a steroid 5-alpha-reductase inhibitor, approved for the treatment of androgenetic alopecia (AGA) and benign prostate hyperplasia. In some patients the treatment is associated with adverse side effects that could become persistent after therapy discontinuation, resulting in the so-called post-finasteride syndrome (PFS). A pharmacogenetic component in the response to finasteride treatment was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
